Skip to content

13F-HR filed by Sarissa Capital Management LP

Sarissa Capital Management LP filed this 13F-HR for the quarter ended 2017-03-31, filed 2017-05-15, with 11 holding rows worth $253,055,000.

Accession
0001140361-17-020718
Filed
2017-05-15
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q1 2017

A holdings report, 11 entries on the cover page, a total value of $253,055,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $253,055,000 with VALUE read as thousands by filing date, 13F file number 028-15935. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
MEDICINES CO584688105COM1,752,000$85,672,000thousands by filing date
BIOGEN INC COM09062X103Stock310,000$84,760,000thousands by filing date
INNOVIVA INC45781M101COM3,425,000$47,367,000thousands by filing date
NOVELION THERAPEUTICS INC67001K202COM NEW1,025,000$11,008,000thousands by filing date
BIOVERATIV INC09075E100COM155,000$8,441,000thousands by filing date
INTRA-CELLULAR THERAPIES INC46116X101COMMON STOCK360,000$5,850,000thousands by filing date
APRICUS BIOSCIENCES INC03832V307COM NEW1,447,906$3,055,000thousands by filing date
VIVUS INC928551100COM2,573,943$2,882,000thousands by filing date
ADVAXIS INC007624208COM NEW339,180$2,771,000thousands by filing date
AbbVie,Inc.00287Y109COM10,000$651,000thousands by filing date
AVEO PHARMACEUTICALS INC053588109COM1,013,616$598,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001140361-17-020718this filing2017-05-15acceptance time not in the bulk data set